AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02538744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxazosin
Description: Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
Study NCT02538744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
Study NCT02538744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
Study NCT02538744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cocaine
Description: On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
Study NCT02538744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cocaine
Description: On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
Study NCT02538744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02538744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05963334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin/paclitaxel
Description: Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
Study NCT05963334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel
Description: Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
Study NCT01895075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Description: Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
Study NCT01895075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2 ml normal saline by inhalation
Study NCT03120884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI
Description: A technique that involves microinjection of spermatozoa into mature oocytes.
Study NCT03120884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF
Description: A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
Study NCT03912012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol renal clearance measurement
Description: intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.
Study NCT03912012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: microcirculation assessment through Laser Doppler associated to iontophoresis.
Description: endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
Study NCT03912012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement
Description: carotid ultrasound (during Day 1)
Study NCT03912012 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: 37 mL of blood sample will be performed at Day 1
Study NCT03912012 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Urine sampling
Description: The urinary collection will be done during the Day 1, on the first morning urination
Study NCT03912012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-resolution peripheral quantitative computed tomography (HR-pQCT)
Description: assessment of the Body Mass Index by HR-pQCT (during the Day 1)
Study NCT03912012 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Dual-energy X-ray (DXA)
Description: assessment of bone parameters by DXA (during the Day 1)
Study NCT01546103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 1000 IU by mouth, once daily for 3 months.
Study NCT01546103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 5000 IU by mouth, once daily for 3 months.
Study NCT00517764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
Study NCT02616510 — intervention group
Intervention type: PROCEDURE
Intervention: cardiovascular screening
Description: cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
Study NCT02385929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing therapy & resistance training
Description: i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards.
Study NCT02490683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luna Rich X
Study NCT02490683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
Study NCT02490683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reliv Now
Study NCT03081702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
Study NCT03081702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is approved and used for the treatment of certain systemic fungal infections.
Study NCT02724332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: 2mg,po,bid
Study NCT01299844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Peer Counseling
Description: 16 Home visits from a bilingual/bicultural diabetes peer counselor.
Study NCT02738814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: When severe emergence agitation(PAED > 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
Study NCT02694744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: 8.4 g/day starting dose, administered orally
Study NCT02694744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patiromer
Description: 8.4 g/day starting dose, administered orally
Study NCT03442816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHRC Camera
Description: Evaluate the technical capabilities of the device to obtain quality images in reflectance and fluorescence imaging modes in a diverse population.
Study NCT00686777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alfa-2b
Description: Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
Study NCT00686777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 400 mg/day orally
Study NCT04942587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LISTENING TO THE RECORDINGS SAYING BY PARENTS
Description: The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.
Study NCT04383509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
Study NCT04383509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
Study NCT00792844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-K capsule formulation
Description: Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
Study NCT00792844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bio-K drink
Description: Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
Study NCT02571426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: anesthetic agent
Study NCT02571426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: anesthetic agent
Study NCT01663870 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audio Recorded Interviews
Description: Audio recorded interview at beginning of visit and after using HealthATM website.
Study NCT01663870 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group Session
Description: Focus group session taking 60-90 minutes.
Study NCT01663870 — intervention group
Intervention type: OTHER
Intervention: Website Session
Description: 10-15 minute session with the HealthATM website.
Study NCT01663870 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion at end of audio recorded interview taking about 5 minutes.
Study NCT05683847 — intervention group
Intervention type: OTHER
Intervention: User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)
Description: Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
Study NCT02969798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg/day
Study NCT02969798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg/day
Study NCT02969798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: the dose will increase from 15 mg/day to 30 mg/day at month two
Study NCT02969798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: starting at 1000 mg/day and increased to 2000 mg/day at month 2.
Study NCT02160080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
Description: Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
Study NCT02715739 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00003468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT00655265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride film-coated tablets
Description: tablets
Study NCT00655265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT04694222 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nd:YAG laser
Description: For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
Study NCT04694222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd:YAG laser
Description: For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
Study NCT00739401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprarenal Proximal Cuff Extension
Description: Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
Study NCT03863184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib, oral, 100 mg BID, continuous
Study NCT03863184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
Study NCT03863184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
Study NCT02737007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK3191607
Description: \[14C\]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of \[14C\]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of \[14C\] radioactivity.
Study NCT01892670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donation of 1 whole blood unit
Description: Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
Study NCT02527681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole medocaril
Description: Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
Study NCT02006316 — intervention group
Intervention type: PROCEDURE
Intervention: Microsurgical subinguinal varicocelectomy
Study NCT01059097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Study NCT01773317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation
Description: All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
Study NCT01773317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
Study NCT04396535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study NCT04396535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT04396535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT04532671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Poly ether ether ketone (PEEK)
Description: PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread
Study NCT04532671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CADCAM Poly ether ether ketone (PEEK)
Description: Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK
Study NCT04532671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: indirect resin composite
Description: CADCAM resin composite blocks using milling process
Study NCT00660725 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vandetanib
Description: Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
Study NCT00660725 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 30-minute IV infusion of 1000 mg/m\^2 gemcitabine on Day 1 of each 14-day cycle.
Study NCT00660725 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m\^2 oxaliplatin on Day 1 of each 14-day cycle.
Study NCT03155165 — intervention group
Intervention type: DEVICE
Intervention: Retroview™ colonoscope
Description: The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
Study NCT03630835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99mTc-Annexin-V-128 uptake on scintigraphy
Description: An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours.
Study NCT00551759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: given IV
Study NCT00551759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: given IV
Study NCT00551759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: given IV
Study NCT00551759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: given IV
Study NCT00551759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
Study NCT00551759 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.